<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02935842</url>
  </required_header>
  <id_info>
    <org_study_id>EILT</org_study_id>
    <nct_id>NCT02935842</nct_id>
  </id_info>
  <brief_title>Evaluation of Intensive Language Therapy</brief_title>
  <acronym>EILT</acronym>
  <official_title>Effectiveness of High-frequency Specific Speech Therapy on Verbal Fluency Decline and/ or Verbal Apraxia in Patients With Parkinson's Disease With and Without Deep Brain Stimulation (DBS) - a Randomized Controlled Single-blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to Parkinson's Disease (PD) speech and language (SL) deficits may occur. Further, the
      literature reports that PD patients, who have not undergone deep brain stimulation (DBS),
      have deficits regarding voice quality (e.g. loudness and intelligibility of their voice),
      while PD patients who have undergone DBS suffer from deficits in word retrieval and speech
      apraxia symptoms. To-date, therapeutic approaches focusing specifically on SL deficits
      observed in PD-DBS patients are yet to be developed and evaluated.

      Therefore, this study investigates the short-and longterm effectiveness of specific and
      intensive, high-frequency speech-language therapy in terms of reducing SL-deficits compared
      to a nonspecific and non-verbal sham treatment (i.e. a rhythmic balance-movement training
      (rBMT)) as well as to a 'no-therapy' condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the course of Parkinson's disease (PD) speech and language (SL) deficits may often emerge.
      In addition, severe verbal fluency (VF) decline has been repeatedly observed in the context
      of deep brain stimulation (DBS) in PD. Interestingly, while PD non-DBS patients have deficits
      with respect to loudness and intelligibility of their voice, PD patients who have undergone
      DBS (PD-DBS) suffer rather from difficulties in semantic and phonemic word retrieval, and
      from speech apraxia symptoms.

      However, to-date and to the best of our knowledge, therapeutic approaches focusing
      specifically on SL deficits observed in PD-DBS patients are yet to be developed and evaluated
      regarding their effectiveness. Thus, this study investigates the short-and longterm
      effectiveness of specific and intensive, high-frequency speech-language therapy in terms of
      reducing SL-deficits compared to a nonspecific and non-verbal sham treatment (i.e. a rhythmic
      balance-movement training (rBMT)) as well as to a 'no-therapy' condition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">October 24, 2018</completion_date>
  <primary_completion_date type="Actual">September 12, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Velocity in Gait</measure>
    <time_frame>At Baseline (BL), T1 after 4 weeks (4W-directly after intervention), T2 after 6 months (6M).</time_frame>
    <description>Gait Velocity: meters per second</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cadence in Gait</measure>
    <time_frame>At Baseline (BL), T1 after 4 weeks (4W-directly after intervention), T2 after 6 months (6M).</time_frame>
    <description>4-Weeks and 6-Months Follow-up. To measure rhythmicity in gait, participants walked 6 metres at their individual pace. They were timed and amount of steps were counted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Speech Velocity</measure>
    <time_frame>At Baseline (BL), T1 after 4 weeks (4W-directly after intervention), T2 after 6 months (6M).</time_frame>
    <description>Speech Velocity at 4 weeks and at 6 months
To measure rhythmicity in speech, participants read a text aloud ('the north wind and the sun') and were recorded using an Olympus. According to these speech samples, the count of elicited syllables per second was calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Speech Cadence</measure>
    <time_frame>At Baseline (BL), T1 after 4 weeks (4W-directly after intervention), T2 after 6 months (6M).</time_frame>
    <description>Speech Cadence 4 Weeks and at 6 Months To measure rhythmicity in speech, participants' speech was recorded while reading a text aloud ('the north wind and the sun'). Elicited syllables per inspiration were analysed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Status (UPDRS)</measure>
    <time_frame>At Baseline and 6 Months</time_frame>
    <description>The complete questionnaire 'Unified Parkinson's Disease Rating Scale' (UPDRS) was filled out at BL and 6M.
Scores may range from 0-4 per question. Final scores may add up to 199 points maximum. The higher the score, the worse disease severity/ degree of disability is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Self-rating Questionnaires</measure>
    <time_frame>At 4 Weeks and 6 Months</time_frame>
    <description>Self-rating questionnaires investigating depression using the Beck's Depression Inventory (BDI).
This is a 21 question, multiple choice, self-report questionnaire. Minimum score is 0 and maximum scores is 63. The higher the score the more severe is the depression.
Details:
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Standardised Test Battery</measure>
    <time_frame>At 4 Weeks and at 6 Months</time_frame>
    <description>Inhibition Control (Stroop), Visio-Construction (Mosaic), Flexibility (Trail Making Test), Episodic Memory (Basel Verbal Learning Test -long delayed free recall), Working Memory (backwards digit span task by Wechsler).
Scores were standardized (z-scores) to a mean of 0 and standard deviation of 1. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population. Negative numbers indicate values lower than the reference population and positive numbers indicate values higher than the reference population</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Specific SL-therapy for PD (with and without DBS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rhythmic specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rBMT for PD (with and without DBS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD (with and without DBS); no therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No further recruiting necessary, as data is already at hand via previous research projects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls; no therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No further recruiting necessary, as data is already at hand via previous research projects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Specific SL-therapy</intervention_name>
    <description>Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.</description>
    <arm_group_label>Specific SL-therapy for PD (with and without DBS)</arm_group_label>
    <arm_group_label>rBMT for PD (with and without DBS)</arm_group_label>
    <other_name>Specific, intensive and high-frequency SL-therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rhythmic Balance-Movement Training (rBMT)</intervention_name>
    <description>Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.</description>
    <arm_group_label>Specific SL-therapy for PD (with and without DBS)</arm_group_label>
    <arm_group_label>rBMT for PD (with and without DBS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for all groups:

          -  The patient is able to cooperate

          -  The patient has the mental competence to provide informed consent to participate in
             the study

          -  The patient speaks and understands German

        Specific Inclusion Criteria for the DBS Group

          -  Fulfilling the above stated inclusion criteria as stated in a, b and c above

          -  The patient is responsive to Levodopa (L-DOPA)

          -  Having received or being scheduled for DBS

        Exclusion Criteria:

          -  Severe psychiatric disease difficult to treat (compulsive disorder, depression, mania,
             psychosis, anxiety as outlined in International Classification of Diseases (ICD-10)
             (WHO 2015, current version).

          -  Patient with dementia (DMS-V, Mini-Mental-Status-Test (MMS) &lt;24, Montreal Cognitive
             Assessment (MoCa) &lt;21)

          -  Secondary Parkinsonism

          -  Age ≤18 years

          -  Pregnancy (early onset)

          -  Presence of a known disease other than PD that shortens the life expectancy

          -  Mental incompetence to provide informed consent to participate in the study

          -  Previous intracranial surgery

          -  Epilepsy

          -  Contraindications for DBS seen in MRI-scan (malignant tumour, severe microvascular
             disease)

          -  Insufficient skills of German language for participating in neuropsychological
             evaluations

          -  Sensory problems, severe enough to significantly interfere with neuropsychological
             assessment

          -  Alcohol and/or drug addiction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Fuhr, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <results_first_submitted>October 31, 2019</results_first_submitted>
  <results_first_submitted_qc>May 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2020</results_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Word Retrieval</keyword>
  <keyword>Apraxia Symptoms</keyword>
  <keyword>Dysarthria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT02935842/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From May 2015 to February 2018, N=32 patients with idiopathic Parkinson’s disease (PD) were recruited from the University Hospital Basel (Switzerland) and N=22 healthy controls (HC) were recruited from senior health centers or sports groups independent of the hospital.</recruitment_details>
      <pre_assignment_details>Eligibility assessments were conducted by neurologists, neuropsychologists and speech-language therapists. Eligibility criteria led to 12 exclusions in the PD group and to 4 exclusions in the HC group.
Therefore, final N count for the study were: N=20 PD patients and N=18 HC.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>rSLT, Then no Therapy, Then rBMT</title>
          <description>Specific, intensive and high-frequency speech-language-therapy (rSLT). Approx. 45 Min. per session, 3 times per week for 4 weeks
Specific SL-therapy: Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
Please note: this was a case-crossover study. Participants, who completed the above stated and described intervention, had then the opportunity to switch to the 'no therapy' group. After having completed the 6 months 'no therapy' period, the participant could enrol again into the 'rhythmic balance-movement training'' rBMT).</description>
        </group>
        <group group_id="P2">
          <title>rBMT, Then 'no Therapy', Then rSLT</title>
          <description>Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
Rhythmic Balance-Movement Training (rBMT): Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.
Please note: this was a case-crossover study. Participants, who completed the above stated and described intervention, had then the opportunity to switch to the 'no therapy' group. After having completed the 6-months period as 'no therapy', the participant could switch to the 'rhythmic speech-language therapy' group (rSLT).</description>
        </group>
        <group group_id="P3">
          <title>No Therapy, Then rSLT, Then rBMT</title>
          <description>&quot;the 6-months-waiting list&quot;. Patients with Parkinson's disease (PD) who had to wait for/ or chose to receive treatments at a later time.
Please note: this was a case-crossover study. After completing the 6-month waiting list (no therapy), participants had then the opportunity to switch to another study arm (being 'rhythmic speech-language therapy' (rSLT) or 'rhythmic balance-movement training' (rBMT). After having completed the second intervention program, the participant could enrol again into a study arm, which he/she has not been before (i.e. either 'rhythmic speech-language therapy' (rSLT) or 'rhythmic balance-movement training'' rBMT).</description>
        </group>
        <group group_id="P4">
          <title>Healthy Controls; no Therapy</title>
          <description>Healthy Controls received no therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Testing and Therapy Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0">Due to limited staff capacity, HC have only been included in the final tranche.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Testing and Therapy Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0">Due to limited staff capacity, HC have only been included in the final tranche.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Testing and Therapy Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="18">HC received no interventions. They have only been tested at BL, 4 Weeks and 6 Months.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Required other therapy (dysphagia)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Accident prior to treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>In this cross-over study, there were 20 PD patients and 18 healthy controls enrolled (HC final N=17, because on participant was lost to Follow-up).This baseline analysis gives all information per group, and PD patients could switch between the different groups (i.e. rSLT, rBMT, NT).</population>
      <group_list>
        <group group_id="B1">
          <title>rSLT, Then no Therapy, Then rBMT</title>
          <description>Specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
Specific SL-therapy: Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
Then participants could be allocated to the no-therapy group, and after 6-month completion again into the rBMT intervention.</description>
        </group>
        <group group_id="B2">
          <title>rBMT, Then rSLT, Then no Therapy</title>
          <description>Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
Rhythmic Balance-Movement Training (rBMT): Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.
Then participants could be enrolled in the rSLT group, and after 6-month completion again into the 'no-therapy' group.</description>
        </group>
        <group group_id="B3">
          <title>No Therapy, Then rSLT or rBMT, Then rBMT or rSLT</title>
          <description>&quot;the 6-months-waiting list&quot;. PD patients who had to wait for/ or chose to receive treatments at a later time.
After 6-month completion, participants could enrol in the rSLT or the rBMT intervention program, and then upon 6-month completion again in the opposite intervention program, being rBMT or rSLT, respectively.</description>
        </group>
        <group group_id="B4">
          <title>Healthy Controls; no Therapy</title>
          <description>Healthy Controls received no therapy.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="17"/>
                    <count group_id="B5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.4" spread="7.1"/>
                    <measurement group_id="B2" value="69.9" spread="6.7"/>
                    <measurement group_id="B3" value="65.1" spread="6.7"/>
                    <measurement group_id="B4" value="67.9" spread="5.2"/>
                    <measurement group_id="B5" value="68.9" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="17"/>
                    <count group_id="B5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="17"/>
                    <count group_id="B5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Speech Velocity</title>
          <units>spoken syllables per second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="17"/>
                    <count group_id="B5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.3" spread=".6"/>
                    <measurement group_id="B2" value="5.3" spread=".6"/>
                    <measurement group_id="B3" value="4.9" spread=".4"/>
                    <measurement group_id="B4" value="2.3" spread="1.6"/>
                    <measurement group_id="B5" value="4.4" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Speech Cadence</title>
          <units>Spoken syllables per inspiration</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="17"/>
                    <count group_id="B5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.4" spread="3.5"/>
                    <measurement group_id="B2" value="9" spread="3.9"/>
                    <measurement group_id="B3" value="8.2" spread=".6"/>
                    <measurement group_id="B4" value="21.6" spread=".6"/>
                    <measurement group_id="B5" value="12.2" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gait velocity</title>
          <units>meters per second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="17"/>
                    <count group_id="B5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" spread=".4"/>
                    <measurement group_id="B2" value="1.2" spread=".4"/>
                    <measurement group_id="B3" value="1.2" spread=".3"/>
                    <measurement group_id="B4" value=".8" spread=".08"/>
                    <measurement group_id="B5" value="1.2" spread=".4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gait Cadence</title>
          <units>steps per second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="17"/>
                    <count group_id="B5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" spread=".8"/>
                    <measurement group_id="B2" value="2.7" spread=".8"/>
                    <measurement group_id="B3" value="2.7" spread=".7"/>
                    <measurement group_id="B4" value="1.7" spread=".2"/>
                    <measurement group_id="B5" value="2.5" spread=".8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Velocity in Gait</title>
        <description>Gait Velocity: meters per second</description>
        <time_frame>At Baseline (BL), T1 after 4 weeks (4W-directly after intervention), T2 after 6 months (6M).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Specific SL-therapy for PD-DBS and Non-DBS</title>
            <description>Specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
Specific SL-therapy: Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.</description>
          </group>
          <group group_id="O2">
            <title>rBMT for PD-DBS and Non-DBS</title>
            <description>Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
Rhythmic Balance-Movement Training (rBMT): Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.</description>
          </group>
          <group group_id="O3">
            <title>PD-DBS/ Non-DBS; no Therapy</title>
            <description>&quot;the 6-months-waiting list&quot;. PD patients who had to wait for/ or chose to receive treatments at a later time.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls; no Therapy</title>
            <description>Healthy Controls received no therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Velocity in Gait</title>
          <description>Gait Velocity: meters per second</description>
          <units>meter per second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gait Velocity-4W (4Weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread=".2"/>
                    <measurement group_id="O2" value="1.2" spread=".3"/>
                    <measurement group_id="O3" value="1.2" spread=".3"/>
                    <measurement group_id="O4" value=".8" spread=".08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gait Velocity-6M (6 Months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread=".8"/>
                    <measurement group_id="O2" value="1.2" spread=".4"/>
                    <measurement group_id="O3" value="1.2" spread=".3"/>
                    <measurement group_id="O4" value=".8" spread=".08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>First Reliable Change (RC), Reliable Change Index (RCI) were calculated on every individual score. Further, ANOVAs and t-tests were administered in order to verify differences between groups or interventions. Significance levels were set at p &lt; .05.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>Reliable Change / Reliable Change Index according to Jacobson &amp; Truax (1991). There, on the basis of every individual score, the change in performance (i.e. BL-4Weeks/ BL-6Months) has been calculated and is reported with level of significance as well as effect size.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cadence in Gait</title>
        <description>4-Weeks and 6-Months Follow-up. To measure rhythmicity in gait, participants walked 6 metres at their individual pace. They were timed and amount of steps were counted.</description>
        <time_frame>At Baseline (BL), T1 after 4 weeks (4W-directly after intervention), T2 after 6 months (6M).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Specific SL-therapy for PD (With and Without DBS)</title>
            <description>Rhythmic specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
Specific SL-therapy: Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
Rhythmic Balance-Movement Training (rBMT): Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.</description>
          </group>
          <group group_id="O2">
            <title>rBMT for PD (With and Without DBS)</title>
            <description>Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
Specific SL-therapy: Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
Rhythmic Balance-Movement Training (rBMT): Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.</description>
          </group>
          <group group_id="O3">
            <title>PD (With and Without DBS); no Therapy</title>
            <description>No further recruiting necessary, as data is already at hand via previous research projects.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls; no Therapy</title>
            <description>No further recruiting necessary, as data is already at hand via previous research projects.</description>
          </group>
        </group_list>
        <measure>
          <title>Cadence in Gait</title>
          <description>4-Weeks and 6-Months Follow-up. To measure rhythmicity in gait, participants walked 6 metres at their individual pace. They were timed and amount of steps were counted.</description>
          <units>steps per second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gait Cadence-4W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread=".3"/>
                    <measurement group_id="O2" value="2.5" spread=".6"/>
                    <measurement group_id="O3" value="2.7" spread=".7"/>
                    <measurement group_id="O4" value="1.7" spread=".2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gait Cadence-6M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread=".8"/>
                    <measurement group_id="O2" value="2.7" spread=".8"/>
                    <measurement group_id="O3" value="2.7" spread=".7"/>
                    <measurement group_id="O4" value="1.7" spread=".2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Speech Velocity</title>
        <description>Speech Velocity at 4 weeks and at 6 months
To measure rhythmicity in speech, participants read a text aloud ('the north wind and the sun') and were recorded using an Olympus. According to these speech samples, the count of elicited syllables per second was calculated.</description>
        <time_frame>At Baseline (BL), T1 after 4 weeks (4W-directly after intervention), T2 after 6 months (6M).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rSLT, Then no Therapy, Then rBMT</title>
            <description>Specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
Specific SL-therapy: Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
Then participants could be allocated to the no-therapy group, and after 6-month completion again into the rBMT intervention.</description>
          </group>
          <group group_id="O2">
            <title>rBMT, Then rSLT, Then no Therapy</title>
            <description>Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
Rhythmic Balance-Movement Training (rBMT): Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.
Then participants could be enrolled in the rSLT group, and after 6-month completion again into the 'no-therapy' group.</description>
          </group>
          <group group_id="O3">
            <title>No Therapy, Then rSLT or rBMT, Then rBMT or rSLT</title>
            <description>&quot;the 6-months-waiting list&quot;. PD patients who had to wait for/ or chose to receive treatments at a later time.
After 6-month completion, participants could enrol in the rSLT or the rBMT intervention program, and then upon 6-month completion again in the opposite intervention program, being rBMT or rSLT, respectively.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls; no Therapy</title>
            <description>Healthy Controls received no therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Speech Velocity</title>
          <description>Speech Velocity at 4 weeks and at 6 months
To measure rhythmicity in speech, participants read a text aloud ('the north wind and the sun') and were recorded using an Olympus. According to these speech samples, the count of elicited syllables per second was calculated.</description>
          <units>spoken syllables per second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Speech velocity 4W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread=".7"/>
                    <measurement group_id="O2" value="4.2" spread=".9"/>
                    <measurement group_id="O3" value="4.9" spread=".7"/>
                    <measurement group_id="O4" value="2.3" spread=".6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Speech velocity 6M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread=".8"/>
                    <measurement group_id="O2" value="4.8" spread=".9"/>
                    <measurement group_id="O3" value="4.9" spread=".6"/>
                    <measurement group_id="O4" value="2.3" spread=".6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Speech Cadence</title>
        <description>Speech Cadence 4 Weeks and at 6 Months To measure rhythmicity in speech, participants' speech was recorded while reading a text aloud ('the north wind and the sun'). Elicited syllables per inspiration were analysed.</description>
        <time_frame>At Baseline (BL), T1 after 4 weeks (4W-directly after intervention), T2 after 6 months (6M).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rSLT, Then no Therapy, Then rBMT</title>
            <description>Specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
Specific SL-therapy: Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
Then participants could be allocated to the no-therapy group, and after 6-month completion again into the rBMT intervention.</description>
          </group>
          <group group_id="O2">
            <title>rBMT, Then rSLT, Then no Therapy</title>
            <description>Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
Rhythmic Balance-Movement Training (rBMT): Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.
Then participants could be enrolled in the rSLT group, and after 6-month completion again into the 'no-therapy' group.</description>
          </group>
          <group group_id="O3">
            <title>No Therapy, Then rSLT or rBMT, Then rBMT or rSLT</title>
            <description>&quot;the 6-months-waiting list&quot;. PD patients who had to wait for/ or chose to receive treatments at a later time.
After 6-month completion, participants could enrol in the rSLT or the rBMT intervention program, and then upon 6-month completion again in the opposite intervention program, being rBMT or rSLT, respectively.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls; no Therapy</title>
            <description>Healthy Controls received no therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Speech Cadence</title>
          <description>Speech Cadence 4 Weeks and at 6 Months To measure rhythmicity in speech, participants' speech was recorded while reading a text aloud ('the north wind and the sun'). Elicited syllables per inspiration were analysed.</description>
          <units>spoken syllables per inspiration</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Speech Cadence 4W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="3.6"/>
                    <measurement group_id="O2" value="13.1" spread="4.7"/>
                    <measurement group_id="O3" value="10.9" spread="3.9"/>
                    <measurement group_id="O4" value="21.6" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Speech Cadence 6M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="4.6"/>
                    <measurement group_id="O2" value="13.6" spread="4.7"/>
                    <measurement group_id="O3" value="10.5" spread="3.5"/>
                    <measurement group_id="O4" value="21.6" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Status (UPDRS)</title>
        <description>The complete questionnaire 'Unified Parkinson's Disease Rating Scale' (UPDRS) was filled out at BL and 6M.
Scores may range from 0-4 per question. Final scores may add up to 199 points maximum. The higher the score, the worse disease severity/ degree of disability is.</description>
        <time_frame>At Baseline and 6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Specific SL-therapy for PD-DBS and Non-DBS</title>
            <description>Specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
Specific SL-therapy: Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.</description>
          </group>
          <group group_id="O2">
            <title>rBMT for PD-DBS and Non-DBS</title>
            <description>Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
Rhythmic Balance-Movement Training (rBMT): Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.</description>
          </group>
          <group group_id="O3">
            <title>PD-DBS/ Non-DBS; no Therapy</title>
            <description>&quot;the 6-months-waiting list&quot;. PD patients who had to wait for/ or chose to receive treatments at a later time.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls; no Therapy</title>
            <description>Healthy Controls received no therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Status (UPDRS)</title>
          <description>The complete questionnaire 'Unified Parkinson's Disease Rating Scale' (UPDRS) was filled out at BL and 6M.
Scores may range from 0-4 per question. Final scores may add up to 199 points maximum. The higher the score, the worse disease severity/ degree of disability is.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UPDRS-BL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" spread="19.1"/>
                    <measurement group_id="O2" value="37.3" spread="20.6"/>
                    <measurement group_id="O3" value="42.8" spread="20.2"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UPDRS-6M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6" spread="16.7"/>
                    <measurement group_id="O2" value="41.7" spread="19.1"/>
                    <measurement group_id="O3" value="37" spread="20.1"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychiatric Self-rating Questionnaires</title>
        <description>Self-rating questionnaires investigating depression using the Beck's Depression Inventory (BDI).
This is a 21 question, multiple choice, self-report questionnaire. Minimum score is 0 and maximum scores is 63. The higher the score the more severe is the depression.
Details:
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression.</description>
        <time_frame>At 4 Weeks and 6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Specific SL-therapy for PD-DBS and Non-DBS</title>
            <description>Specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
Specific SL-therapy: Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.</description>
          </group>
          <group group_id="O2">
            <title>rBMT for PD-DBS and Non-DBS</title>
            <description>Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
Rhythmic Balance-Movement Training (rBMT): Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.</description>
          </group>
          <group group_id="O3">
            <title>PD-DBS/ Non-DBS; no Therapy</title>
            <description>&quot;the 6-months-waiting list&quot;. PD patients who had to wait for/ or chose to receive treatments at a later time.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls; no Therapy</title>
            <description>Healthy Controls received no therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychiatric Self-rating Questionnaires</title>
          <description>Self-rating questionnaires investigating depression using the Beck's Depression Inventory (BDI).
This is a 21 question, multiple choice, self-report questionnaire. Minimum score is 0 and maximum scores is 63. The higher the score the more severe is the depression.
Details:
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BDI-4W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="1.8"/>
                    <measurement group_id="O2" value="7.6" spread="2.1"/>
                    <measurement group_id="O3" value="7.1" spread="1.9"/>
                    <measurement group_id="O4" value="5.5" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BDI-6M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="1.7"/>
                    <measurement group_id="O2" value="8.8" spread="1.6"/>
                    <measurement group_id="O3" value="8.3" spread="1.8"/>
                    <measurement group_id="O4" value="5.4" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Standardised Test Battery</title>
        <description>Inhibition Control (Stroop), Visio-Construction (Mosaic), Flexibility (Trail Making Test), Episodic Memory (Basel Verbal Learning Test -long delayed free recall), Working Memory (backwards digit span task by Wechsler).
Scores were standardized (z-scores) to a mean of 0 and standard deviation of 1. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population. Negative numbers indicate values lower than the reference population and positive numbers indicate values higher than the reference population</description>
        <time_frame>At 4 Weeks and at 6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Specific SL-therapy for PD-DBS and Non-DBS</title>
            <description>Specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
Specific SL-therapy: Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.</description>
          </group>
          <group group_id="O2">
            <title>rBMT for PD-DBS and Non-DBS</title>
            <description>Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
Rhythmic Balance-Movement Training (rBMT): Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.</description>
          </group>
          <group group_id="O3">
            <title>PD-DBS/ Non-DBS; no Therapy</title>
            <description>&quot;the 6-months-waiting list&quot;. PD patients who had to wait for/ or chose to receive treatments at a later time.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls; no Therapy</title>
            <description>Healthy Controls received no therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Standardised Test Battery</title>
          <description>Inhibition Control (Stroop), Visio-Construction (Mosaic), Flexibility (Trail Making Test), Episodic Memory (Basel Verbal Learning Test -long delayed free recall), Working Memory (backwards digit span task by Wechsler).
Scores were standardized (z-scores) to a mean of 0 and standard deviation of 1. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population. Negative numbers indicate values lower than the reference population and positive numbers indicate values higher than the reference population</description>
          <units>z-scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Episodic Memory-4W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.9" spread="1.7"/>
                    <measurement group_id="O2" value="-.3" spread="1.2"/>
                    <measurement group_id="O3" value="-.7" spread=".3"/>
                    <measurement group_id="O4" value="-.4" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Episodic Memory-6M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.7" spread="1.5"/>
                    <measurement group_id="O2" value="-.6" spread=".8"/>
                    <measurement group_id="O3" value="-.3" spread="1.1"/>
                    <measurement group_id="O4" value="-.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Working Memory-4W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".6" spread=".8"/>
                    <measurement group_id="O2" value=".2" spread=".9"/>
                    <measurement group_id="O3" value="-.2" spread=".8"/>
                    <measurement group_id="O4" value=".1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Working Memory-6M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.3" spread="1.1"/>
                    <measurement group_id="O2" value=".13" spread=".9"/>
                    <measurement group_id="O3" value="-.2" spread=".8"/>
                    <measurement group_id="O4" value="-.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visuo-Construction-4W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".4" spread="1.03"/>
                    <measurement group_id="O2" value=".14" spread="1.1"/>
                    <measurement group_id="O3" value=".4" spread=".9"/>
                    <measurement group_id="O4" value=".4" spread=".8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visa-Construction-6M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".03" spread="1"/>
                    <measurement group_id="O2" value=".07" spread=".9"/>
                    <measurement group_id="O3" value=".2" spread=".6"/>
                    <measurement group_id="O4" value=".8" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inhibition (Stroop)-4W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".6" spread=".8"/>
                    <measurement group_id="O2" value=".8" spread="1.4"/>
                    <measurement group_id="O3" value=".7" spread=".9"/>
                    <measurement group_id="O4" value=".2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inhibition (Stroop)-6M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.04" spread=".9"/>
                    <measurement group_id="O2" value=".3" spread=".6"/>
                    <measurement group_id="O3" value=".7" spread=".7"/>
                    <measurement group_id="O4" value=".4" spread=".7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flexibility (TMT)-4W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.4" spread=".8"/>
                    <measurement group_id="O2" value="-.6" spread="1.3"/>
                    <measurement group_id="O3" value="-.8" spread=".3"/>
                    <measurement group_id="O4" value=".2" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flexibility (TMT)-6M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.6" spread="1.02"/>
                    <measurement group_id="O2" value="-1.2" spread="1.1"/>
                    <measurement group_id="O3" value="-.3" spread=".8"/>
                    <measurement group_id="O4" value=".8" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected over the full length of the study for each participant. Beginning at the baseline measurement up to 1 year after completion.</time_frame>
      <desc>This cross-over study involved non-invasive intensive treatments (i.e. rhythmic speech therapy vs. rhythmic balance-mobility training).</desc>
      <group_list>
        <group group_id="E1">
          <title>Specific SL-therapy for PD-DBS and Non-DBS</title>
          <description>Specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
Specific SL-therapy: Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.</description>
        </group>
        <group group_id="E2">
          <title>rBMT for PD-DBS and Non-DBS</title>
          <description>Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
Rhythmic Balance-Movement Training (rBMT): Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.</description>
        </group>
        <group group_id="E3">
          <title>PD-DBS/ Non-DBS; no Therapy</title>
          <description>&quot;the 6-months-waiting list&quot;. PD patients who had to wait for/ or chose to receive treatments at a later time.</description>
        </group>
        <group group_id="E4">
          <title>Healthy Controls; no Therapy</title>
          <description>Healthy Controls received no therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Peter Fuhr</name_or_title>
      <organization>University Hospital Basel</organization>
      <phone>0041 61 265 ext 41 66</phone>
      <email>peter.fuhr@usb.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

